CGP 71683 hydrochlorideCat. No. 2199 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: N-[[trans-4-[[(4-Amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide hydrochloride |
Biological Activity
Extremely selective, non-peptide NPY Y5 receptor antagonist. Displays > 1000-fold selectivity over Y1, Y2 and Y4 receptors; IC50 values are 1.4, 2765, 7187 and 5637 nM at cloned rat Y5, Y1, Y2 and Y4 receptors respectively. Potently inhibits NPY-induced food intake following i.p. administration in diabetic, free-feeding and fasted rats.Certificate of Analysis / Safety Data Sheet
References
Criscione et al (1998) Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J.Clin.Invest. 102 2136. PMID: 9854049.
Dumont et al (2000) Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). Can.J.Physiol.Pharmacol. 78 116. PMID: 10737674.
Lecklin et al (2002) Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. Br.J.Pharmacol. 135 2029. PMID: 11959807.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: CGP 71683 hydrochloride, supplier, selective, potent, non-peptide, NPY, Y5, receptor, antagonists, Neuropeptide, Y, Receptors, CGP71683, hydrochloride, neuropeptides
Quick Order
Find multiple products by catalog number
New Products in this Area
Oxytocin analog
ML 221Apelin receptor (APJ) antagonist
Q94 hydrochlorideNegative allosteric modulator at PAR1 receptor
FSLLRY-NH2PAR2 peptide antagonist
SB 611812Urotensin-II (UT) antagonist; attenuates cardiac dysfunction
TC-MCH 7cSelective melanin-concentrating hormone receptor 1 (MCH1R) antagonist
CYM 9484Potent NPY Y2 receptor antagonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.







